The Cancer Pharmacology Annual
Author : B. A. Chabner
Publisher :
Page : 181 pages
File Size : 11,78 MB
Release : 1983
Category : Antineoplastic agents
ISBN : 9789021930893
Author : B. A. Chabner
Publisher :
Page : 181 pages
File Size : 11,78 MB
Release : 1983
Category : Antineoplastic agents
ISBN : 9789021930893
Author : B. A. Chabner
Publisher : Elsevier Science & Technology
Page : 181 pages
File Size : 11,32 MB
Release : 1983-01-01
Category : Antineoplastic agents
ISBN : 9780444903259
Author : Bruce A. Chabner
Publisher :
Page : 10 pages
File Size : 50,85 MB
Release : 1968
Category : Tumors
ISBN :
Author : Bruce A. Chabner
Publisher : Elsevier Science & Technology
Page : 228 pages
File Size : 25,7 MB
Release : 1984-01-01
Category :
ISBN : 9780444903488
Author : B.A. Chabner
Publisher : Elsevier Science & Technology
Page : 216 pages
File Size : 36,46 MB
Release : 1985-01-01
Category :
ISBN : 9780444904003
Author : Bruce A. Chabner
Publisher :
Page : 223 pages
File Size : 16,47 MB
Release : 1986
Category : Antineoplastic agents
ISBN : 9780444904300
Author : Paul Workman
Publisher : Springer Science & Business Media
Page : 244 pages
File Size : 44,97 MB
Release : 2012-12-06
Category : Medical
ISBN : 3642778747
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.
Author : Ashkan Emadi, MD, PhD
Publisher : Springer Publishing Company
Page : 471 pages
File Size : 36,81 MB
Release : 2023-10-06
Category : Medical
ISBN : 0826149332
Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs, Second Edition is a visually engaging reference detailing the essential basic and clinical science of all approved, effective, and life-prolonging drug therapies in oncology. Now with a greater emphasis on clinical context, application, and management in each chapter, this significantly revised edition provides both early-career and seasoned clinicians with a practical, bench-to-bedside approach and patient-oriented guide. The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that is directly necessary and applicable when at the patient’s bedside. Everything from traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents is explored, in addition to a new chapter covering pharmacogenomics. Accompanied by elegant illustrations, each chapter details the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic and molecular properties of the various agents, and their mechanisms of action. The book covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Thoroughly updated to include new FDA-approved treatments and applications, and written by leading experts in cancer pharmacology, this second edition continues to be a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology, including clinicians, pharmacists, nurses, and trainees. Key Features: Over 150 beautiful illustrations depict structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents Contains more than 160 high-yield hematology and oncology board-style chapter review questions (more than double the previous edition) with descriptive rationales Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work, and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other treatment modalities Thoroughly updated and revised chapters cover new FDA drug approvals, disease-site indications, clinical applications and management of drug-to-drug interactions, and toxicities Discusses challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments Provides important pharmacotherapy context with clinical pearls in each chapter that help support a patient-oriented, bedside approach
Author : G. Mathe
Publisher : Springer Science & Business Media
Page : 354 pages
File Size : 21,30 MB
Release : 2012-12-06
Category : Medical
ISBN : 3642814883
Local treatment cures about 30 to 40% of cancers, this proportion depending on the follow-up required to establish it. This means that 60 to 70% of the malignant neoplasias are disseminated either perceptibly (leukemias, visible metas tases) or imperceptibly, forming a 'minimal imperceptible disease', which local treatment leaves, whether it consists of surgery, radiotherapy, or surgery plus radiotherapy. When the neoplastic tissue is voluminous enough to be per ceptible, cures can be obtained with chemotherapy or chemo immunotherapy. When the neoplastic disease is imperceptible, made up of micrometastases, it apparently can be cured by systemic postsurgical chemotherapy, immunotherapy, or chemoimmunotherapy. Hence there is the need for intensive development of these medical therapies which are applied by the medical oncol ogist and, at present, consist of chemotherapy, immuno therapy, or chemoimmunotherapy. These medical thera peutics can only grow with scientific development, the main weapon of which is experimental and clinical pharmacology. These volumes report the communications presented at the 1979 EORTC Annual Plenary Session on Cancer Chemo and Immunopharmacology.
Author : Guiseppe Giaccone
Publisher : Elsevier
Page : 0 pages
File Size : 37,95 MB
Release : 2005-06
Category : Medical
ISBN : 9780444518835
This 22nd Volume of CANCER CHEMOTHERAPY & BIOLOGICAL RESPONSE MODIFIERS continues in the tradition of providing a timely review of progress and achievements in clinical oncology. The emphasis of Annual 22 is on recent advances in the understanding of anti-cancer drugs, specific malignancies and biological response modifiers. The section on drugs includes new chapters on the clinical use of epidermal growth factor receptor pathways and on angiogenesis pathway inhibitors. These agents have moved rapidly from preclinical models to demonstrated clinical efficacy and are becoming part of comprehensive oncologic care. The section on tumours provides detailed updates on past year's advances in the understanding of risk, classification, staging and management of common malignancies. The section on biologics provides chapters on active immunotherapy through vaccines or cytokine administration, exciting perspectives on the modification of T cells to recognise tumours using tumour-reactive monoclonal antibody, and an important review detailing the effect of conventional cancer treatment on the patient's immune system. The special section within Annual 22 is devoted to recent advances in the understanding and treatment of melanoma. Special detail is included regarding advances in screening, prevention and predisposition for this increasingly frequent disease, in addition to chapters on surgical treatment and biologic response modifiers interventions. Chapters on the uses of interferon, and on other cytokines combined with chemotherapy, summarise how and when these approaches have proven to be useful. Four chapters then review separate classes of immunologic interventions for melanoma.